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β-lactam antibiotics, such as penicillin, 
are among the most commonly prescribed 
group of antibiotics. These antibiotics are 
characterized by a four-membered β-lactam 
ring in their molecular structure, and they 
act by binding to transpeptidase enzymes 
found exclusively in bacteria, also called 
penicillin binding proteins (PBPs). Once 
the β-lactam binds to this target, bacterial 
cell wall biosynthesis is disrupted and the 
bacteria lyse and die. 
Unfortunately, due to the heavy use of 
these antibiotics, bacteria developed 
mechanisms that can render β-lactams 
inactive and lead to resistance. Antibiotic 
resistance in humans and in animals poses 
a serious public health threat and is a 
growing health concern worldwide. 
One mechanism for bacterial resistance to 
β-lactam antibiotics is the production of 
a β-lactamase enzyme that hydrolyzes the 
β-lactam ring of the antibiotic, making 
the antibiotic ineffective against its target, 
the bacterial cell wall transpeptidase. 
Currently, there are four recognized classes 
of β-lactamases (A-D) classified by their 
unique mechanism for destroying β-lactam 
antibiotics.  Classes A, C and D act by a 
serine based mechanism for destruction 
which involves a two-step acylation/
deacylation reaction. Despite their increasing 
clinical importance, class D β-lactamases are 
among the least understood.  To date, about 
250 known class D β-lactamases have been 
identified. OXA-1 is a member of the non-
carbapenem-hydrolyzing subgroup of the 
class D β-lactamases and the first discovered.
 β-lactamase inhibitors were created in an 
effort to combat these resistance enzymes. 
Due to the similarities in structures of 
both the β-lactam antibiotic substrate 
and the inhibitor, bacteria have rapidly 
evolved to develop mechanisms to resist 
the inhibitors as well. Unfortunately, the 
common clinical β-lactamase inhibitors 
do not often inhibit class D β-lactamases. 
Therefore, the major goal to studying the 
class D β-lactamase OXA-1 is to discover 
a competitive inhibitor that does not have 
a structure similar to β-lactam compounds 
because bacteria would not be able to 
quickly evolve to develop mechanisms to 
resist these non-β-lactam molecules. 
The discovery of a novel inhibitor for an 
enzyme target is a challenging task. We 
have chosen a structure-based approach 
using DOCK, a molecular docking 
program. DOCK computationally predicts 
binding conformations of a database 
of small molecules within a target site 
on the enzyme. The ZINC database of 
commercially available compounds was 
used in our docking calculations and 
allowed for millions of small compounds 
to be screened against the target OXA-
1 active site. Compounds were ranked 
by favorable interaction energies, and 
the top compounds in the list suggested 
possibilities for potential inhibitors. In part, 
interaction energies are calculated based on 
the size and shape of the molecule, as well 
as the non-covalent interactions between 
the molecule and OXA-1 active site. The 
top hits, or compounds most likely to 
inhibit based on their docking score, were 
experimentally tested. 
Structure-based docking led to the 
identification of several novel leads that 
inhibit OXA-1 β-lactamase. So far, 13 
compounds from the lead-like subset have 
been ordered and tested experimentally 
for inhibition of OXA-1. Of the 13 
compounds tested, five inhibited OXA-
1 with a Ki < 1 mM. Optimization of 
a novel series of OXA-1 inhibitors is 
currently underway. 
*This scholar and faculty mentor have 
requested that only an abstract be 
published.
